• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

No #AAAS and ASM you do not deserve good PR for freeing up a few papers on Ebola
Saw a PR from AAAS about how they were freeing up all of ~ 20 papers on Ebola In light of what has become the largest Ebola outbreak on record, Science and Science Translational Medicine have compiled over a decade's worth of their published news and research. Researchers and the general public can now view this special collection for free.OK. More access is good. But alas, they did not even free up all papers in #AAAS journals with Ebola in the Title or Abstract.And then I started thinking. What about HIV? TB? Malaria? And as I started Tweeting about this, I saw that ASM also was hopping on the "free Ebola" bandwagon (act...
Source: The Tree of Life - August 20, 2014 Category: Medical Scientists Authors: Jonathan Eisen Source Type: blogs

Voices for Vaccines: 11 Facts Show How it’s a Propaganda Ploy for Emory University, CDC, and Big Pharma
Conclusion The Voices for Vaccines program at the Task Force for Global Health may be administered by a few mothers, but they are not the ones pulling the strings behind the scenes. The information in this article reveals who keeps the lights on for the website and the Task Force organization as a whole. Furthermore, the past, present and future relationships with the Centers for Disease Control, Emory University, and pharmaceutical companies should immediately raise a red flag for any parent. Especially when the message calls for you to blindly trust doctors injecting dangerous chemicals into your child. If you want to ta...
Source: vactruth.com - February 19, 2014 Category: Health Medicine and Bioethics Commentators Authors: Jeffry John Aufderheide Tags: Jeffry John Aufderheide Top Stories Alan Hinman Deborah Wexler Emory University Paul Offit Stanley Plotkin Task Force for Global Health U.S. Centers for Disease Control and Prevention Voices for Vaccines Source Type: blogs

IFPMA Millennium Development Goals
In 2000, the Millennium Development Goals (MDGs) set out in motion a landmark political agenda from the highest levels of national governments to be achieved by 2015. Through eight overarching goals, governments and international organizations committed to improving the social and economic conditions especially in the world's poorest countries. A recent report from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) looked at several of these goals, which strongly relate to life science companies. Specifically, the report looked at goals related to: Reducing child mortality Improvi...
Source: Policy and Medicine - December 24, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs

The Situation of Secret Pleasures (more on Dan Wegner’s Work)
This excerpt, which highlights some of the remarkable work by the late Dan Wegner, comes from an article written by Eric Jaffe in a 2006 edition of the APS’s Observer: “Freud’s Fundamental Rule of Psychoanalysis was for patients to be completely open with a therapist no matter how silly or embarrassing the thought,” says Anita Kelly, a researcher at the University of Notre Dame who published one of the first books on the formal study of secrets, The Psychology of Secrets, in 2002. Only since the late 1980s and early 1990s have researchers like Daniel Wegner and James Pennebaker put Freud through the empirical r...
Source: The Situationist - July 18, 2013 Category: Psychiatrists and Psychologists Authors: The Situationist Staff Tags: Emotions Life Morality Social Psychology Source Type: blogs

How Drug Companies Keep Medicine Out of Reach - The Atlantic
http://www.theatlantic.com/health/archive/2013/05/how-drug-companies-keep-medicine-out-of-reach/275853/?ReutersFor almost a decade, the United States has been standing in the way of an idea that could lead to cures for some of the world's most devastating illnesses. The class of maladies is known as neglected diseases, and they almost exclusively affect those in the developing world. The same idea, if realized, might also be used in more affluent nations to goad the pharmaceutical industry into producing critical innovations that the free market has yet to produce - things like new antibiotics, which are likely to be used ...
Source: PharmaGossip - May 15, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

Drug donations are great, but should Big Pharma be setting the agenda?
Monday 29 April 2013 12.01 BST Critics fear that giving out free medicines allows pharmaceutical companies to decide which diseases are treated Vaccine donations might end after a period of time, leaving governments to pick up the bill. Photograph: Chris Hondros/Getty Images Adam Robert Green for African Arguments, part of the Guardian Africa Network In the early 2000s, pharmaceutical companies were high on activists' hit lists, prompted by Big Pharma's ill-advised attempt to sue the South African government for patent infringement on HIV drugs; an attempt to deal with the country's epidemic by allowing cheaper, generi...
Source: PharmaGossip - April 30, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs

Another cancer we can prevent
Although no one talks about it much, one of the results of the AIDS epidemic has been that there has been an increase in the number of men diagnosed with anal cancer. This cancer arises in the anus, about a half-inch inside and above the opening. The first symptom is itching that doesn’t go away and then soreness and bleeding and finally, pain. In my practice, the only patients I saw with this were women. I wasn’t sure why until the discovery of HPV (Human Papilloma Virus). Not only is this the virus that causes cervical cancer and is sexually transmitted but now we know it also causes anal cancer. It isn’t clear wh...
Source: Dr.Kattlove's Cancer Blog - April 24, 2013 Category: Oncologists Source Type: blogs

PhRMA Report: Over 5400 Medicines in Development and 70% are First in Class
According to report released by PhRMA, companies have more than 5,400 medicines in development globally, and more than 70% of therapies in the pipeline are potentially first-in-class and could offer patients new treatment options, and a notable number of potential therapies target diseases with limited treatment options such as ALS and rare diseases.  A breakdown of their report offers insight into the various medicines in development for different diseases and populations.    Older Americans  America’s biopharmaceutical research companies are developing 465 new medicines that target the 10 leading chronic conditi...
Source: Policy and Medicine - April 24, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs

2012: Banner Year for New Drugs
Fueled by new cancer therapeutics, last year the annual new molecular and biological entity approval count from the U.S. Food and Drug Administration (FDA) saw its highest year since 1997. One-third of the novel products approved by the FDA’s Center for Drug Evaluation and Research (CDER) are used to treat cancers of the blood, breast, colon, prostate, skin and thyroid. As part of the U.S. Food and Drug Administration (FDA), the Center for Drug Evaluation and Research (CDER) promotes and protects the health of Americans by assuring that all prescription and over-the-counter drugs are safe and effective. The CDE...
Source: Highlight HEALTH - February 13, 2013 Category: Medical Scientists Authors: Walter Jessen, Ph.D. Source Type: blogs

Pages: 1  2  3  4